All News

13 August 2008

Morphotek(R), Inc. Announces License Agreement for the Development of a Monoclonal Antibody to Treat Prostate CancerAntibodies

13 August 2008

Global Phase 3 Study of IMC-1121B in Metastatic Breast Cancer CommencesAntibodies

13 August 2008

ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company’s TAP TechnologyAntibodies

12 August 2008

MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alphaAntibodies

11 August 2008

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 AntagonistAntibodies

11 August 2008

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast CancerAntibodies

10 August 2008

FDA Extends Review Timeline for Ustekinumab Biologic License Application Three MonthsAntibodies

7 August 2008

InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625Antibodies

6 August 2008

Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical TrialAntibodies

5 August 2008

Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical TrialAntibodies

5 August 2008

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105Antibodies

5 August 2008

YM Biosciences Reports Phase II Data for Nimotuzumab in Metastatic Colorectal CancerAntibodies

3 August 2008

Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.Antibodies

31 July 2008

Phase II Data on Lilly’s Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer’s DiseaseAntibodies

31 July 2008

Seattle Genetics Initiates SGN-70 Phase I Clinical TrialAntibodies

31 July 2008

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal StudyAntibodies

30 July 2008

Elan and Wyeth Present Encouraging Results from Phase 2 Clinical Trial of Bapineuzumab at International Conference on Alzheimer’s DiseaseAntibodies

30 July 2008

FDA Advisory Committee recommends approval of Actemra for the treatment of rheumatoid arthritisAntibodies

28 July 2008

Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis TrialAntibodies

23 July 2008

Merck Receives European Approval for Broader Use of Erbitux in Metastatic Colorectal Cancer Including First-Line TreatmentAntibodies

23 July 2008

MorphoSys Licenses RapMAT Technology to AstellasAntibodies

23 July 2008

Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeuticsAntibodies

22 July 2008

Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License AgreementAntibodies

22 July 2008

Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple SclerosisAntibodies

21 July 2008

Goodwin Biotechnology’s Manufactured Melanin-Binding Antibody Used in Successful Melanoma TrialAntibodies

19 July 2008

The Multiple Myeloma Research Consortium (MMRC) Announces the Initiation of Phase I/II Study of Elotuzumab (Huluc63) Monoclonal Antibody in Combination with VelcadeAntibodies

17 July 2008

Bradmer Reports Progression Free Survial Data from Previous Phase II Glioblastoma Multiforme TrialsAntibodies

17 July 2008

MediGene exercises option for Anti-L1 Monoclonal Antibody and continues collaboration with DKFZ (German Cancer Research Center)Antibodies

16 July 2008

Symphogen and Biovitrum have Initiated a Novel Treatment Study in Autoimmune Bleeding Disorder (ITP) PatientsAntibodies

16 July 2008

Merck: Erbitux Approved for Use in Metastatic Colorectal Cancer in JapanAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

5T4-Targeted Immunotherapy Candidates Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Nectin-4-Targeted Immunotherapy Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics